The CCSN webinar series is of interest to patients, survivors, family, friends, caregivers, and any member of the community interested in the best possible care and follow-up for cancer patients and survivors. The impact of volunteering and taking positive action to effect change are important elements in the transition to post-treatment life.
Rare Cancers: The Time to Act is Now
Date held: April 11th, 2019
Presented by: Durhane Wong-Rieger, President & CEO of Canadian Organization for Rare Disorders and Lisa Machado, Founder and Chair of the CML Network
Diagnostic breakthroughs like genome sequencing make earlier stage diagnosis possible and breakthroughs in personalized treatment, including cell and gene therapies, provide new hope, including potential cures.
CCSN welcomed our host panelist Durhane Wong-Rieger, President & CEO of Canadian Organization for Rare Disorders and Chair of Rare Disease International. Durhane was joined by Lisa Machado, Founder and Chair of the CML Network for this engaging and educational webinar on the unique issues presented in rare cancers.
The webinar was followed by a question & answer session.
What is patient engagement at CADTH, and how can you get involved?
Date held: April 4th, 2019
Presented by: Bill Dempster, CEO of 3Sixty Public Affairs with guest panelists Sarah Berglas (CADTH) and Maureen Smith (CORD)
CCSN welcomed CADTH’s Patient Engagement Officer Sarah Berglas to hear more about the many aspects in which CADTH involves patients in its work. Bill and Sarah walked through opportunities for patients and others to become involved in CADTH’s work, including:
- Providing patient input to CADTH’s pan-Canadian Oncology Drug Review (pCODR)
- Involving patients in CADTH’s assessments of medical devices, interventions, diagnostic tests, and procedures
- CADTH’s new Patient and Community Advisory Committee and
- CADTH’s newly published patient engagement framework.
There are other opportunities outside of the formal reviews, as well, and Sarah spoke further about what CADTH heard from its listening exercise with patient groups last fall. Sarah also spoke about how patients will be involved in CADTH’s upcoming annual symposium on April 14-16 in Edmonton.
Maureen Smith also joined Bill and Sarah, sharing her experience convening public and patient members on Canadian HTA bodies to discuss our experiences, learn from experts and each other.
This is a must-see webinar for the engaged, the curious and the novice!
Cancer and Heart Disease – Where the two intersect
Date held: March 28th, 2019
Presented by: Dr. Susan Dent
We have made great strides in the treatment of cancer. More individuals are surviving a cancer diagnosis, but cancer treatments can have a detrimental impact on cardiovascular health.
Dr. Susan Dent, a medical oncologist who co-founded the first multidisciplinary cardio-oncology clinic in Canada, discussed the importance of optimizing cardiovascular health for patients during and following completion of their cancer treatment.
The webinar was followed by a question & answer session.
Anal & Colorectal Cancer
Date held: March 21st, 2019
Presented by: Helene Hutchings of Anal Cancer – A Bum Rap
For Colorectal Cancer Awareness Month, CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available. She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
CDIAC to CADTH: How the pan-Canadian Oncology Drug Review (pCODR) is changing to accommodate provincial cancer agency needs
Date held: March 14th, 2019
Presented by: Gerry Jeffcott, 3Sixty Public Affairs with guest panelists Louise Binder & Martine Elias
This webinar was hosted by Gerry Jeffcott from 3Sixty Public Affairs. He summarized some important changes that the Canadian Agency for Drugs and Technologies in Health (CADTH) has proposed to the way pCODR reviews new cancer medications and outline the current consultation process.
Following the CADTH summary, patient representatives Louise Binder (Save Your Skin Foundation) and Martine Elias (Myeloma Canada) offered their perspective on the proposals and helped frame the patient feedback.
After hearing from CADTH and the patients, there was time for an interactive question and answer session.
Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue)
Date held: March 7th, 2019
Presented by: Dr. Kelvin Chan
Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which is a pan-Canadian collaboration working on developing a framework to generate and use real-world evidence to inform cancer drug funding decisions. The webinar was followed by an interactive question & answer session.
How Timely is Canada’s Medication Review and Approval Process?
Date held: January 24th, 2019
Presented by: Gerry Jeffcott, 3Sixty Public Affairs with Nigel Rawson & Sarah Lussier
This presentation was hosted by Gerry Jeffcott from 3Sixty Public Affairs, who was joined by two pharmaceutical policy researchers who have conducted analyses of Canada’s access performance over time and in comparison with other countries.
The session began with an overview of each of the elements of the Canadian review and approval process by our moderator. After that, the session explored each agency’s performances in terms of supporting efficient access to needed new medicines. We will also compare Canada with other similar countries to determine how we fare internationally in terms of gaining access.
The presentation includes an interactive question and answer session.